-- Hims & Hers Health (HIMS) shares rose over 7% pre-bell Thursday after a senior US health official signaled plans to ease restrictions on certain peptides.
The US Food and Drug Administration will remove 12 peptides from its category 2 list, with the substances set for review by an advisory committee in July, US Health and Human Services Secretary Robert Kennedy Jr. said in a post on X.
The changes could expand regulated access to peptide-based treatments and shift demand away from black markets, Kennedy said.
Price: $26.16, Change: $+1.87, Percent Change: +7.70%